174 related articles for article (PubMed ID: 34022872)
21. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
22. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.
Kessler R; Keusch G; Szucs TD; Wittenborn JS; Hoerger TJ; Brügger U; Wieser S
Swiss Med Wkly; 2012; 142():w13508. PubMed ID: 22307760
[TBL] [Abstract][Full Text] [Related]
23. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors.
Chen AB; Punglia RS; Kuntz KM; Mauch PM; Ng AK
J Clin Oncol; 2009 Nov; 27(32):5383-9. PubMed ID: 19752333
[TBL] [Abstract][Full Text] [Related]
26. Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.
Liu Y; Xu H; Lv L; Wang X; Kang R; Guo X; Wang H; Zheng L; Liu H; Guo L; Chen Q; Liu S; Qiao Y; Zhang S
BMC Med; 2024 Feb; 22(1):73. PubMed ID: 38369461
[TBL] [Abstract][Full Text] [Related]
27. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis.
Gu S; Shi L; Shao H; Wang X; Hu X; Gu Y; Dong H
BMC Med; 2020 Dec; 18(1):378. PubMed ID: 33267884
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
Zhang X; Liu S; Li Y; Wang Y; Tian M; Liu G
PLoS One; 2016; 11(6):e0156393. PubMed ID: 27304904
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
32. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.
Tunis SL; Minshall ME
Am J Manag Care; 2008 Mar; 14(3):131-40. PubMed ID: 18333705
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
34. Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective.
Zhuo X; Zhang P; Selvin E; Hoerger TJ; Ackermann RT; Li R; Bullard KM; Gregg EW
Am J Prev Med; 2012 Apr; 42(4):374-81. PubMed ID: 22424250
[TBL] [Abstract][Full Text] [Related]
35. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.
Laxy M; Wilson ECF; Boothby CE; Griffin SJ
Value Health; 2017 Dec; 20(10):1288-1298. PubMed ID: 29241888
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.
Robotham JV; Deeny SR; Fuller C; Hopkins S; Cookson B; Stone S
Lancet Infect Dis; 2016 Mar; 16(3):348-56. PubMed ID: 26616206
[TBL] [Abstract][Full Text] [Related]
37. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.
Grzeszczak W; Czupryniak L; Kolasa K; Sciborski C; Lomon ID; McEwan P
Diabetes Technol Ther; 2012 Jan; 14(1):65-73. PubMed ID: 22066527
[TBL] [Abstract][Full Text] [Related]
39. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.
Kahn R; Alperin P; Eddy D; Borch-Johnsen K; Buse J; Feigelman J; Gregg E; Holman RR; Kirkman MS; Stern M; Tuomilehto J; Wareham NJ
Lancet; 2010 Apr; 375(9723):1365-74. PubMed ID: 20356621
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of screening for oral cancer in primary care.
Speight PM; Palmer S; Moles DR; Downer MC; Smith DH; Henriksson M; Augustovski F
Health Technol Assess; 2006 Apr; 10(14):1-144, iii-iv. PubMed ID: 16707071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
